Susana Sainz de la Maza Selected Research

Therapeutics

4/2023	Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies.
8/2022	The effect of timing of high-efficacy therapy on processing speed performance in multiple sclerosis.
4/2021	Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment.
12/2020	Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.
1/2020	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.
2/2014	Acute ischemic stroke in a 12-year-old successfully treated with mechanical thrombectomy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susana Sainz de la Maza Research Topics

Disease

14	Multiple Sclerosis 08/2023 - 01/2016
2	Relapsing-Remitting Multiple Sclerosis 01/2024 - 01/2021
2	Progressive Multifocal Leukoencephalopathy 03/2022 - 03/2019
2	Lymphopenia (Lymphocytopenia) 03/2022 - 03/2019
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 04/2021 - 01/2021
2	Myelitis 01/2018 - 04/2016
2	Ischemic Stroke 02/2014 - 01/2014
1	Infections 12/2022
1	Chronic Progressive Multiple Sclerosis 01/2022
1	Inflammation (Inflammations) 01/2022
1	COVID-19 04/2021
1	Neoplasms (Cancer) 04/2021
1	Meningitis 01/2018
1	Nervous System Diseases (Neurological Disorders) 01/2018
1	Encephalitis (Encephalitis, Rasmussen) 01/2018
1	Central Nervous System Infections (Central Nervous System Infection) 01/2018
1	Central Nervous System Diseases (CNS Diseases) 01/2018
1	Transverse Myelitis (Necrotizing Myelitis) 04/2016
1	Ganglion Cysts (Ganglion) 01/2016
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 02/2014
1	Neurologic Manifestations (Neurological Manifestations) 02/2014
1	Hematuria 01/2014
1	Stroke (Strokes) 01/2014
1	Metrorrhagia (Spotting) 01/2014
1	Hemorrhage 01/2014
1	Cerebral Hemorrhage 01/2014

Drug/Important Bio-Agent (IBA)

6	Dimethyl FumarateIBA 03/2022 - 03/2019
3	Oligoclonal BandsIBA 01/2023 - 01/2016
2	Alemtuzumab (Campath)FDA Link 01/2024 - 01/2021
2	Immunoglobulins (Immunoglobulin)IBA 01/2023 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2021
2	LipidsIBA 01/2020 - 01/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 04/2016
2	Foscarnet FDA LinkGeneric 01/2018 - 04/2016
1	VaccinesIBA 08/2023
1	COVID-19 VaccinesIBA 04/2023
1	Immunoglobulin G (IgG)IBA 12/2022
1	Rituximab (Mabthera)FDA Link 12/2022
1	ocrelizumabIBA 01/2022
1	SteroidsIBA 04/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2021
1	Immunoglobulin M (IgM)IBA 01/2021
1	AntibodiesIBA 01/2020
1	Natalizumab (Tysabri)FDA Link 01/2020
1	EnzymesIBA 01/2019
1	teriflunomideIBA 01/2019
1	Dihydroorotate DehydrogenaseIBA 01/2019
1	pyrimidineIBA 01/2019
1	Ganciclovir (Cytovene)FDA LinkGeneric 01/2018
1	Methylprednisolone FDA LinkGeneric 04/2016
1	AutoantibodiesIBA 01/2016
1	Retinaldehyde (Retinal)IBA 01/2016
1	Dabigatran FDA Link 01/2014
1	Warfarin (Coumadin)FDA LinkGeneric 01/2014

Therapy/Procedure

6	Therapeutics 04/2023 - 02/2014
2	Artificial Respiration (Mechanical Ventilation) 04/2021 - 01/2021
1	Aftercare (After-Treatment) 03/2022
1	Precision Medicine 01/2020
1	Thrombectomy 02/2014